Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 38.41 1.99% 0.75
OLMA closed up 3.43 percent on Friday, March 5, 2021, on 1.98 times normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical OLMA trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 1.99%
Stochastic Buy Signal Bullish 1.99%
Lizard Bullish Bullish Day Trade Setup 1.99%
Lower Bollinger Band Walk Weakness 1.99%
New 52 Week Low Weakness 1.99%
Wide Bands Range Expansion 1.99%
Lower Bollinger Band Touch Weakness 1.99%
Oversold Stochastic Weakness 1.99%
New 52 Week Closing Low Bearish 5.49%
New 52 Week Low Weakness 5.49%
Older End-of-Day Signals for OLMA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lizard Bullish Entry 32 minutes ago
Hammer Candlestick Entry 32 minutes ago
Rose Above Previous Day's High 32 minutes ago
Up 3% 32 minutes ago
Up 2% 32 minutes ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Hormones Targeted Therapy Epidermal Growth Factor Receptor Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant

Is OLMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 60.27
52 Week Low 32.115
Average Volume 91,804
200-Day Moving Average 0.00
50-Day Moving Average 44.97
20-Day Moving Average 45.69
10-Day Moving Average 41.17
Average True Range 3.76
ADX 20.54
+DI 14.64
-DI 31.63
Chandelier Exit (Long, 3 ATRs ) 43.46
Chandelier Exit (Short, 3 ATRs ) 43.39
Upper Bollinger Band 56.81
Lower Bollinger Band 34.58
Percent B (%b) 0.14
BandWidth 48.66
MACD Line -2.21
MACD Signal Line -0.91
MACD Histogram -1.3017
Fundamentals Value
Market Cap 1.51 Billion
Num Shares 40.2 Million
EPS
Price-to-Sales 0.00
Price-to-Book 15.95
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 47.27
Resistance 3 (R3) 46.49 42.50 45.67
Resistance 2 (R2) 42.50 40.06 42.89 45.13
Resistance 1 (R1) 40.08 38.55 41.29 40.86 44.60
Pivot Point 36.10 36.10 36.70 36.49 36.10
Support 1 (S1) 33.68 33.65 34.89 34.46 30.72
Support 2 (S2) 29.69 32.14 30.08 30.19
Support 3 (S3) 27.27 29.69 29.65
Support 4 (S4) 28.05